http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103599132-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a3febfbd930318f2b7418da1deddb9a
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2008-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c862e55557d4b51e675586e027f4a6a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97035dece76a9434a88d9ea7045abe40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6d2af820bf4cd7cab1da3b44327f6cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6fe633c63054e8e5b7b3dc775e1bbe4
publicationDate 2014-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-103599132-A
titleOfInvention Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
abstract The present invention provides placental perfusate, placental perfusate cells and placenta-derived intermediate natural killer (PINK) cells, and combinations thereof. The present invention also provides compositions comprising placental perfusate, placental perfusate cells, and intermediate natural killer cells from placenta and combinations thereof, and the use of placental perfusate, placental perfusate cells, and intermediates from placenta Natural killer cells and combinations thereof, methods of inhibiting the growth or proliferation of tumor cells, cancer cells, etc. and methods of treating individuals with tumor cells. In a preferred embodiment, the composition comprises: isolated CD56 + , CD16 - natural killer cells.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106047806-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113699107-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113699107-B
priorityDate 2007-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007041954-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10797
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466265299
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467384890
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419551775

Total number of triples: 31.